{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:53:03Z","timestamp":1774054383744,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd004290","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2006,4,19]],"date-time":"2006-04-19T00:00:00Z","timestamp":1145404800000}}],"reference-count":201,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004290.pub2","type":"journal-article","created":{"date-parts":[[2006,5,9]],"date-time":"2006-05-09T20:10:34Z","timestamp":1147205434000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients"],"prefix":"10.1002","author":[{"given":"Angela C","family":"Webster","sequence":"first","affiliation":[{"name":"University of Sydney; School of Public Health; Edward Ford Building A27 Sydney NSW Australia 2006"}]},{"given":"Vincent WS","family":"Lee","sequence":"additional","affiliation":[{"name":"Westmead Hospital; Renal Medicine; Darcy Rd Westmead NSW Australia 2145"}]},{"given":"Jeremy R","family":"Chapman","sequence":"additional","affiliation":[{"name":"Westmead Hospital; Renal Medicine; Darcy Rd Westmead NSW Australia 2145"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[{"name":"The Children's Hospital at Westmead; Centre for Kidney Research; Locked Bag 4001 Westmead NSW Australia 2145"}]}],"member":"311","published-online":{"date-parts":[[2006,4,19]]},"reference":[{"issue":"Suppl 5","key":"10.1002\/14651858.CD004290.pub2-BIB0001|cit1","first-page":"465","article-title":"A comparative, open-label study to evalute graft function in de novo renal allograft recipients treated with reduced-dose or standard-dose cyclosporine in combination with sirolimus and corticosteroids [abstract]","volume":"3","author":"Cohen","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/00007890-200407271-00598","article-title":"Use of sirolimus as initial therapy after renal transplantation: preliminary results of a randomized pilot study in patient receiving marginal kidneys [abstract]","volume":"78","author":"Durrbach","year":"2004","journal-title":"Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD004290.pub2-BIB0003|cit3","first-page":"345","article-title":"Use of sirolimus as initial therapy after renal transplantation: preliminary results of a randomized pilot study in patient receiving marginal kidneys [abstract]","volume":"4","author":"Thervet","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD004290.pub2-BIB0004|cit4","first-page":"450","article-title":"A randomized prospective trial of sirolimus vs cyclosporine in kidney transplantation: renal function and histology at two years [abstract]","volume":"3","author":"Flechner","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD004290.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/00007890-200210270-00002","article-title":"Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine","volume":"74","author":"Flechner","year":"2002","journal-title":"Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00007890-200407271-00374","article-title":"Kidney transplantation with sirolimus and mycophenolate mofetil based immunosuppression preserves renal structure and function at two years compared to calcineurin inhibitor drugs [abstract]","volume":"78","author":"Flechner","year":"2004","journal-title":"Transplantation"},{"issue":"11","key":"10.1002\/14651858.CD004290.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/j.1600-6143.2004.00627.x","article-title":"De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years","volume":"4","author":"Flechner","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD004290.pub2-BIB0008|cit8","first-page":"274","article-title":"Defining the optimal doses of sirolimus and tacrolimus in high-risk cadaveric renal transplant recipients [abstract]","volume":"2","author":"Gaber","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD004290.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/01.TP.0000121504.69676.5E","article-title":"Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation","volume":"77","author":"Lo","year":"2004","journal-title":"Transplantation"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0041-1345(03)00238-0","article-title":"Observations on the use of sirolimus and tacrolimus in high-risk renal transplant recipients","volume":"35","author":"Lo","year":"2003","journal-title":"Transplantation Proceedings"},{"issue":"1","key":"10.1002\/14651858.CD004290.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1399-0012.2004.00116.x","article-title":"Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation","volume":"18","author":"Lo","year":"2004","journal-title":"Clinical Transplantation"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD004290.pub2-BIB0012|cit12","first-page":"288","article-title":"Prospective randomized single center study comparing the impact on long term renal transplant function of two prednisone free maintenance immunosuppressive combinations with tacrolimus (Tac), mycophenolate mofetil (MMF) versus tacrolimus\/sirolimus (SLR) [abstract]","volume":"5","author":"Gallon","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD004290.pub2-BIB0013|cit13","first-page":"463","article-title":"A prospective randomized single center study of rapid corticosteroid eliminiation comparing two maintenance immunosuppressive protocols: tacrolimus (FK506)\/mycophenolate mofetil (MMF) versus tacrolimus\/sirolimus. [abstract]","volume":"3","author":"Gallon","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD004290.pub2-BIB0014|cit14","first-page":"460","article-title":"6 months preliminary results of a randomized trial comparing sirolimus (SRL) versus tacrolimus (FK) in 141 transplant patients receiving a cadaveric renal graft [abstract]","volume":"5","author":"Glotz","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD004290.pub2-BIB0015|cit15","first-page":"208","article-title":"Sirolimus-treated renal transplant recipients experience improved renal function with cyclosporine elimination: one-year results from a phase II trial [abstract]","volume":"16","author":"Campistol","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00007890-200004271-00958","article-title":"Sirolimus (rapamune) permits early elimination of cyclosporine in recipients of cadaveric renal allografts [abstract]","volume":"69","author":"Gonwa","year":"2000","journal-title":"Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004290.pub2-BIB0018|cit17","first-page":"891","article-title":"Sirolimus (srl) treated patients demonstrate improved renal function after withdrawal of cyclosporine (csa) [abstract]","volume":"12","author":"Gonwa","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD004290.pub2-BIB0017|cit18","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1097\/00007890-200212150-00013","article-title":"Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination","volume":"74","author":"Gonwa","year":"2002","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD004290.pub2-BIB0019|cit19","unstructured":"Hricik DE for the Rapamune Renal Function Study Group Sirolimus improves renal function without increasing acute rejection after cyclosporine elimination in renal transplant paitents. [abstract] XVIII International Congress of the Transplantation Society; 2000 Aug 27 - Sep 1; Rome (Italy) 2000"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD004290.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/ajkd.2001.27504","article-title":"Cyclosporine elimination in the presence of TOR inhibitors: Effects on renal function, acute rejection, and safety","volume":"38","author":"Velosa","year":"2001","journal-title":"American Journal of Kidney Diseases"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0022|cit21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00007890-200407271-00698","article-title":"One year results for the first prospective multi-center kidney transplant study comparing tacrolimus+sirolimus vs. tacrolimus+mmf combination therapy [abstract]","volume":"78","author":"Gonwa","year":"2004","journal-title":"Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD004290.pub2-BIB0021|cit22","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/01.TP.0000062837.99400.60","article-title":"Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months","volume":"75","author":"Gonwa","year":"2003","journal-title":"Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004290.pub2-BIB0023|cit23","first-page":"9","article-title":"Final results for the first prospective, multi-center kidney transplant study comparing tacrolimus+mmf combination therapy [abstract]","volume":"14","author":"Gonwa","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD004290.pub2-BIB0024|cit24","first-page":"550","article-title":"Six-month results of the first prospective, randomized, multi-center kidney transplant study comparing tacrolimus+rapamune vs tacrolimus+mmf combination therapy [abstract]","volume":"3","author":"Mendez","year":"2003","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD004290.pub2-BIB0025|cit25","unstructured":"Campistol JM Grinyo JM Paul J Garcia J Arias M Morales JM Sirolimus, TAC and corticosteroides in the postoperative period. Preliminary results [abstract] XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami (USA) 2002"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004290.pub2-BIB0026|cit26","first-page":"101","article-title":"A randomised, open, multicenter, trial comparing tacrolimus (TAC) withdrawal with TAC dose reduction in de novo renal transplants, receiving sirolimus (SIR), TAC and steroids in the postoperative time. Initial results [abstract]","volume":"13","author":"Grinyo","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD004290.pub2-BIB0027|cit27","first-page":"394","article-title":"A randomised, open-label, pilot study to compare the safety and efficacy of tacrolimus (TAC) elimination with tac dose reduction in de novo renal allograft recipients, receiving sirolimus, tac and corticosteroides in the postoperative period. preliminary results. [abstract]","volume":"2","author":"Grinyo","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD004290.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1600-6143.2004.00499.x","article-title":"Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation","volume":"4","author":"Grinyo","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0041-1345(03)00213-6","article-title":"Bicetre hospital experience with sirolimus-based therapy in human renal transplantation: the Sirolimus European Renal Transplant Study","volume":"35","author":"Charpentier","year":"2003","journal-title":"Transplantation Proceedings"},{"issue":"7","key":"10.1002\/14651858.CD004290.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/00007890-199904150-00017","article-title":"Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group","volume":"67","author":"Groth","year":"1999","journal-title":"Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD004290.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1016\/S0041-1345(98)01341-4","article-title":"New trails in transplantation: how to exploit the potential of sirolimus in clinical transplantation","volume":"30","author":"Groth","year":"1998","journal-title":"Transplantation Proceedings"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0041-1345(03)00241-0","article-title":"Cardiovascular risk factors of sirolimus compared with cyclosporine: Early experience from two randomized trials in renal transplantation","volume":"35","author":"Legendre","year":"2003","journal-title":"Transplantation Proceedings"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00007890-200004271-00976","article-title":"Comparison of long term csa - and sirolimus-based therapies on lipid parameters [abstract]","volume":"69","author":"Legendre","year":"2000","journal-title":"Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD004290.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1399-0012.2004.00188.x","article-title":"Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies","volume":"18","author":"Mathew","year":"2004","journal-title":"Clinical Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD004290.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1034\/j.1600-6143.2002.20507.x","article-title":"Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients","volume":"2","author":"Morales","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/00007890-200004271-00954","article-title":"Multicenter, randomized, double-blind, dose-finding study evaluating the efficacy and safety of rad001 (rad) in de novo renal transplant recipients [abstract]","volume":"69","author":"Kahan","year":"2000","journal-title":"Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD004290.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1097\/00007890-200105270-00008","article-title":"RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection","volume":"71","author":"Kahan","year":"2001","journal-title":"Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004290.pub2-BIB0038|cit38","first-page":"475","article-title":"Longitudinal influence of everolimus on cyclosporine assessed over 6 months in two blinded de novo kidney transplant trials [abstract]","volume":"1","author":"Kovarik","year":"2001","journal-title":"American Journal of Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD004290.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1016\/S0041-1345(98)01341-4","article-title":"New trails in transplantation: how to exploit the potential of sirolimus in clinical transplantation","volume":"30","author":"Groth","year":"1998","journal-title":"Transplantation Proceedings"},{"issue":"10","key":"10.1002\/14651858.CD004290.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1097\/00007890-199911270-00016","article-title":"Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group","volume":"68","author":"Kahan","year":"1999","journal-title":"Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD004290.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1067\/mcp.2001.116309","article-title":"Median effect analysis of efficacy versus adverse effects of immunosuppressants","volume":"70","author":"Kahan","year":"2001","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD004290.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1034\/j.1600-6143.2002.20610.x","article-title":"Effects of sirolimus on lipids in renal allograft recipients: An analysis using the Framingham risk model","volume":"2","author":"Blum","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD004290.pub2-BIB0043|cit43","first-page":"289","article-title":"Sirolimus (rapamune): effects on bone in renal transplant patients [abstract]","volume":"69","author":"Campistol","year":"2000","journal-title":"Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004290.pub2-BIB0044|cit44","first-page":"880","article-title":"The effect of sirolimus on lipids on renal transplant recipients: results from clinical trials [abstract]","volume":"12","author":"Campistol","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9225","key":"10.1002\/14651858.CD004290.pub2-BIB0049|cit45","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0140-6736(00)02480-6","article-title":"Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group","volume":"356","author":"Kahan","year":"2000","journal-title":"Lancet"},{"issue":"9225","key":"10.1002\/14651858.CD004290.pub2-BIB0050|cit46","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0140-6736(00)02480-6","article-title":"Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group","volume":"356","author":"Kahan","year":"2000","journal-title":"Lancet"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0051|cit47","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0041-1345(03)00353-1","article-title":"Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation","volume":"35","author":"Kahan","year":"2003","journal-title":"Transplantation Proceedings"},{"issue":"7","key":"10.1002\/14651858.CD004290.pub2-BIB0045|cit48","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/00007890-200110150-00001","article-title":"Rapamycin: clinical results and future opportunities","volume":"72","author":"Kahan","year":"2001","journal-title":"Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD004290.pub2-BIB0046|cit49","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1067\/mcp.2001.116309","article-title":"Median effect analysis of efficacy versus adverse effects of immunosuppressants","volume":"70","author":"Kahan","year":"2001","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0047|cit50","first-page":"361","article-title":"Two-year follow-up of the pivotal multicenter trials of sirolimus [abstract]","volume":"69","author":"Kahan","year":"2000","journal-title":"Transplantation"},{"issue":"Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0048|cit51","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00007890-199905150-00093","article-title":"Pivotal phase III multicenter, randomized, blinded trial of sirolimus versus azathioprine in combination with cyclosporine and prednisone in primary renal transplants [abstract]","volume":"67","author":"Kahan","year":"1999","journal-title":"Transplantation"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00007890-200004271-00957","article-title":"The safety and efficacy of sirolimus\/cyclosporine for the prevention of acute rejection in primary renal allograft recipients [abstract]","volume":"69","author":"Mathew","year":"2000","journal-title":"Transplantation"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00007890-200004271-00962","article-title":"Racial effects on the safety and efficacy of sirolimus in renal transplantation [abstract]","volume":"69","author":"Neylan","year":"2000","journal-title":"Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004290.pub2-BIB0054|cit54","first-page":"324","article-title":"Multi-center phase ii trial of sirolimus in renal transplantataion: safety and efficacy for black patients [abstract]","volume":"3","author":"Neylan","year":"1997","journal-title":"Nephrology"},{"issue":"Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00007890-199904150-00948","article-title":"Effect of race on efficacy & safety of Sirolimus vs AZA + standard immunotherapy in renal transplantation [abstract]","volume":"67","author":"Neylan","year":"1999","journal-title":"Transplantation"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/00007890-200004271-00007","article-title":"One year safety and efficacy of sirolimus after renal transplant [abstract]","volume":"69","author":"Pescovitz","year":"2000","journal-title":"Transplantation"},{"issue":"38","key":"10.1002\/14651858.CD004290.pub2-BIB0057|cit57","first-page":"42","article-title":"Sirolimus reduces acute rejection after kidney transplantation","volume":"140","author":"Wasielewski","year":"2000","journal-title":"Deutsche Apotheker Zeitung"},{"key":"10.1002\/14651858.CD004290.pub2-BIB0058|cit58","doi-asserted-by":"crossref","unstructured":"Non systematic results pooled from Kahan 2001 (157) and MacDonald 2001 (302) See individual studies for reference lists","DOI":"10.1007\/978-1-4302-0854-9_9"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/00007890-200407271-00097","article-title":"A prospective, randomized study of cyclosporine (csa)\/mycophenolate mofetil (mmf) versus tacrolimus (tac)\/sirolimus(sir) with rapid discontinuation of prednisone (p) [abstract]","volume":"78","author":"Kandaswamy","year":"2004","journal-title":"Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD004290.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1600-6143.2005.00885.x","article-title":"A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients--an interim analysis","volume":"5","author":"Kandaswamy","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004290.pub2-BIB0061|cit61","first-page":"475","article-title":"North\/South American, double-blind, parallel group study of the safety and efficacy of certican (rad) versus mycophenolate mofetil (mmf) in combination with neoral and corticosteroids [abstract]","volume":"1","author":"Kaplan","year":"2001","journal-title":"American Journal of Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004290.pub2-BIB0062|cit62","first-page":"899","article-title":"Everolimus (rad) - 12 month pivotal study results; the efficacy and safety in conjunction with neoral\u00ae and steroids [abstract]","volume":"12","author":"Kaplan","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD004290.pub2-BIB0063|cit63","first-page":"185","article-title":"Statin therapy in renal transplant patients receiving everolimus: screening for clinical and pharmacokinetic drug interactions [abstract]","volume":"2","author":"Kovarik","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD004290.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/00007890-200203270-00016","article-title":"Exposure-response relationships for everolimus in de novo kidney transplantation: Defining a therapeutic range","volume":"73","author":"Kovarik","year":"2002","journal-title":"Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD004290.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1034\/j.1600-6143.2003.00107.x","article-title":"Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation","volume":"3","author":"Kovarik","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004290.pub2-BIB0066|cit66","first-page":"475","article-title":"Longitudinal influence of everolimus on cyclosporine assessed over 6 months in two blinded de novo kidney transplant trials [abstract]","volume":"1","author":"Kovarik","year":"2001","journal-title":"American Journal of Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD004290.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1399-0012.2005.00326.x","article-title":"Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data","volume":"19","author":"Lorber","year":"2005","journal-title":"Clinical Transplantation"},{"key":"10.1002\/14651858.CD004290.pub2-BIB0068|cit68","unstructured":"Mendez R Kovarik JM Kaplan B Tedesco-Silva H Kahan BD McMahon L Everolimus pharmacokinetics in de novo kidney allograft recipients: dose-proportional, stable exposure over 6 months [abstract 149] 10th ESOT & 12th ETCO Congress; 2001 Oct 6-11; Lisbon (Portugal) 2001"},{"issue":"1","key":"10.1002\/14651858.CD004290.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1432-2277.2004.00052.x","article-title":"Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation","volume":"18","author":"Oberbauer","year":"2005","journal-title":"Transplant International"},{"key":"10.1002\/14651858.CD004290.pub2-BIB0070|cit70","unstructured":"Tedesco De Silva H Boger R Buren D Kahan B Kaplan B Mendez R Certican (RAD; Everolimus) is complementary with neoral in preventing organ rejection as part of triple therapy in de novo renal transplant recipients 2001 A Transplant Odyssey; 2001 Aug 20-23; Istanbul (Turkey) 2001"},{"key":"10.1002\/14651858.CD004290.pub2-BIB0071|cit71","doi-asserted-by":"crossref","unstructured":"Eris J Cambell S Walker R Russ G Stambe C RAD2307 International Study Group Excellent graft function in de novo transplant recipients treated with everolimus, reduced dose neoral and simulect: 6 months analysis [abstract] Transplantation Society of Australia & New Zealand; 2004 Mar 31-Apr 2; Canberra (Australia) 2004 33","DOI":"10.1097\/00007890-200407271-00095"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00007890-200407271-00095","article-title":"Excellent graft function in de novo kidney transplant recipients treated with certican\u00ae, simulect\u00ae and reduced neoral\u00ae exposure: 12-month results [abstract]","volume":"78","author":"Eris","year":"2004","journal-title":"Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD004290.pub2-BIB0073|cit73","first-page":"786","article-title":"Excellent graft function in de novo kidney transplant recipients treated with concentration controlled everolimus, reduced neoral exposure and basiliximab: 6 months analysis [abstract]","volume":"18","author":"Kramer","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0074|cit74","first-page":"15","article-title":"Concentration-controlled everolimus (Certican): combination with reduced dose calcineurin inhibitors","volume":"79","author":"Pascual","year":"2005","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD004290.pub2-BIB0075|cit75","unstructured":"Rigotti P Excellent graft function in de novo kidney transplant recipients treated with concentration controlled everolimus, reduced neoral exposure and simulect: 6 months analysis [abstract 294] European Society of Transplantation; 2003 Sep; Venice (Italy) 2003"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD004290.pub2-BIB0076|cit76","first-page":"462","article-title":"Efficacy and safety of 2 doses of everolimus combined with reduced dose neoral in de novo kidney transplant recipients: 6 months analysis [abstract]","volume":"3","author":"Tedesco","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD004290.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1600-6143.2004.00389.x","article-title":"Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies","volume":"4","author":"Vitko","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00007890-200004271-00959","article-title":"Sirolimus versus cyclosporine in association with mycophenolate mofetil [abstract]","volume":"69","author":"Kreis","year":"2000","journal-title":"Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD004290.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/00007890-200004150-00009","article-title":"Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients","volume":"69","author":"Kreis","year":"2000","journal-title":"Transplantation"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0041-1345(03)00241-0","article-title":"Cardiovascular risk factors of sirolimus compared with cyclosporine: Early experience from two randomized trials in renal transplantation","volume":"35","author":"Legendre","year":"2003","journal-title":"Transplantation Proceedings"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00007890-200004271-00976","article-title":"Comparison of long term CSA - and sirolimus-based therapies on lipid parameters [abstract]","volume":"69","author":"Legendre","year":"2000","journal-title":"Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD004290.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1399-0012.2004.00188.x","article-title":"Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies","volume":"18","author":"Mathew","year":"2004","journal-title":"Clinical Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD004290.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1034\/j.1600-6143.2002.20507.x","article-title":"Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients","volume":"2","author":"Morales","year":"2002","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD004290.pub2-BIB0084|cit84","unstructured":"Non systematic results pooled from Kreis 2000 (210) and Groth 1999 (207) See individual studies for reference lists"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD004290.pub2-BIB0085|cit85","first-page":"350","article-title":"Comparison of tacrolimus (FK506) and sirolimus(SRL) combination with FK506 and mycophenolate mofetil (MMF) in kidney transplant recipients with steroid avoidance [abstract]","volume":"3","author":"Kumar","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD004290.pub2-BIB0086|cit86","first-page":"578","article-title":"Comparison of efficacy and safety of sirolimus(slr) and mycophenolate mofetil(mmf) as adjunct to calcineurin inhibitor(cni) based steroid free immunosuppression in kidney transplantation [astract]","volume":"4","author":"Kumar","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD004290.pub2-BIB0087|cit87","first-page":"216","article-title":"A prospective randomized study to compare the efficacy and safety of sirolimus (slr) and mycophenolate mofetil (mmf) monitored by protocol biopsies in tacrolimus (tac) based steroid free immunosuppression [abstract]","volume":"4","author":"Kumar","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD004290.pub2-BIB0088|cit88","first-page":"540","article-title":"12 month results of a randomized trial comparing sirolimus (SRL) versus cyclosporine (CsA) in 150 transplant patients receiving a cadaveric renal graft [abstract]","volume":"5","author":"Lebranchu","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD004290.pub2-BIB0089|cit89","first-page":"285","article-title":"Preliminary results of a randomized trial comparing sirolimus (srl) versus cyclosporine (csa) in 150 transplant patients receiving a cadaveric renal graft [abstract]","volume":"4","author":"Lebranchu","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00007890-200407271-01242","article-title":"Preliminary results of a randomized trial comparing sirolimus (srl) versus cyclosporine (csa) in 150 transplant patients receiving a cadaveric renal graft [abstract]","volume":"78","author":"Lebranchu","year":"2004","journal-title":"Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD004290.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1034\/j.1600-6143.2002.20610.x","article-title":"Effects of sirolimus on lipids in renal allograft recipients: An analysis using the Framingham risk model","volume":"2","author":"Blum","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0092|cit92","first-page":"289","article-title":"Sirolimus (rapamune): effects on bone in renal transplant patients [abstract]","volume":"69","author":"Campistol","year":"2000","journal-title":"Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004290.pub2-BIB0093|cit93","first-page":"880","article-title":"The effect of sirolimus on lipids on renal transplant recipients: results from clinical trials [abstract]","volume":"12","author":"Campistol","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD004290.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/00007890-200110150-00001","article-title":"Rapamycin: clinical results and future opportunities","volume":"72","author":"Kahan","year":"2001","journal-title":"Transplantation"},{"issue":"Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/00007890-199905150-00196","article-title":"Triglyceride (tg) elevations in renal transplant recipients treated with sirolimus (rapamycin, rapa) added to a cyclosporine (csa)\/prednisone (pred) regimen [abstract]","volume":"67","author":"Kahan","year":"1999","journal-title":"Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD004290.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1067\/mcp.2001.116309","article-title":"Median effect analysis of efficacy versus adverse effects of immunosuppressants","volume":"70","author":"Kahan","year":"2001","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00007890-199905150-00027","article-title":"A randomized trial of sirolimus, cyclosporine and prednisone vs cyclosporine - prednisone alone in recipients of mismatched first kidney grafts: results at one year [abstract]","volume":"67","author":"MacDonald","year":"1999","journal-title":"Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD004290.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00007890-200101270-00019","article-title":"A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus\/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts","volume":"71","author":"MacDonald","year":"2001","journal-title":"Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD004290.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1399-0012.2004.00188.x","article-title":"Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies","volume":"18","author":"Mathew","year":"2004","journal-title":"Clinical Transplantation"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00007890-200004271-00957","article-title":"The safety and efficacy of sirolimus\/cyclosporine for the prevention of acute rejection in primary renal allograft recipients [abstract]","volume":"69","author":"Mathew","year":"2000","journal-title":"Transplantation"},{"issue":"1-2","key":"10.1002\/14651858.CD004290.pub2-BIB0102|cit101","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0041-1345(00)02317-4","article-title":"Sirolimus is effective for prevention of acute rejection in primary mismatched renal allograft recipients","volume":"33","author":"Ponticelli","year":"2001","journal-title":"Transplantation Proceedings"},{"issue":"3","key":"10.1002\/14651858.CD004290.pub2-BIB0101|cit102","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/S0041-1345(01)01987-X","article-title":"Phase III trial of Rapamune versus placebo in primary renal allograft recipients","volume":"33","author":"Ponticelli","year":"2001","journal-title":"Transplantation Proceedings"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004290.pub2-BIB0103|cit103","first-page":"698","article-title":"Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients on a cyclosporine+rapamycin regimen (phase III protocol 0468602US) [abstract]","volume":"9","author":"Sindhi","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004290.pub2-BIB0104|cit104","first-page":"699","article-title":"A single center 6 month follow up of a phase III trial of sirolimus in a predominantly African-American renal transplant population [abstract]","volume":"9","author":"Sindhi","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00007890-199904150-00949","article-title":"Outcomes of African Americans (AA) in a phase III randomized placebo-controlled trial of sirolimus (SRL) in renal transplantation [abstract]","volume":"67","author":"Sindhi","year":"1999","journal-title":"Transplantation"},{"issue":"1-2","key":"10.1002\/14651858.CD004290.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S0041-1345(00)02421-0","article-title":"A single-center open label randomized trial of the safety and efficacy of the use of sirolimus versus azathioprine in one-haplotype living related kidney transplant recipients-preliminary results","volume":"33","author":"Machado","year":"2001","journal-title":"Transplantation Proceedings"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00007890-200004271-00163","article-title":"A single-center open label randomized trial of the safety and efficacy of the use of rapamune versus azathioprine in one haplotype living related kidney recipients - preliminary results [abstract]","volume":"69","author":"Tedesco","year":"2000","journal-title":"Transplantation"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0041-1345(03)00232-X","article-title":"Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty","volume":"35","author":"Tedesco","year":"2003","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD004290.pub2-BIB0110|cit109","first-page":"284","article-title":"Concentration-controlled use of sirolimus (srl) associated with reduced exposure of cyclosporine (csa) in black patients: 12-month results [abstract]","volume":"4","author":"Ferreira","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0109|cit110","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00007890-200407271-00816","article-title":"Concentration-controlled use of sirolimus (srl) associated with reduced exposure of cyclosporine (csa) in black patients: 12-month results [abstract]","volume":"78","author":"Ferreira","year":"2004","journal-title":"Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD004290.pub2-BIB0111|cit111","first-page":"351","article-title":"Concentration-controlled use of sirolimus (SRL) associated with reduced exposure of cyclosporine (CSA) in black patients [abstract]","volume":"3","author":"Machado","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0041-1345(03)00232-X","article-title":"Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty","volume":"35","author":"Tedesco","year":"2003","journal-title":"Transplantation Proceedings"},{"issue":"5","key":"10.1002\/14651858.CD004290.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/S0041-1345(02)03042-7","article-title":"Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection","volume":"34","author":"Burke","year":"2002","journal-title":"Transplantation Proceedings"},{"issue":"2","key":"10.1002\/14651858.CD004290.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.TP.0000101290.20629.DC","article-title":"A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year","volume":"77","author":"Ciancio","year":"2004","journal-title":"Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD004290.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/01.TP.0000101495.22734.07","article-title":"A randomized long-term trial of tacrolimus\/sirolimus versus tacrolimus\/mycophenolate mofetil versus cyclosporine (NEORAL)\/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year","volume":"77","author":"Ciancio","year":"2004","journal-title":"Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD004290.pub2-BIB0116|cit116","first-page":"484","article-title":"Surgical complications after kidney transplantation: comparing three different immunosuppresive regimenes [abstract]","volume":"3","author":"Mattiazzi","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD004290.pub2-BIB0117|cit117","first-page":"465","article-title":"Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection [abstract]","volume":"3","author":"Miller","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD004290.pub2-BIB0118|cit118","first-page":"471","article-title":"A phase II, open-label, concentration-controlled, randomized 6-month study of standard-dose tacrolimus + sirolimus + corticosteroids compared to reduced-dose tacrolimus + sirolimus + corticosteroids in renal allograft recipients. [abstract].","volume":"2","author":"Bechstein","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD004290.pub2-BIB0119|cit119","first-page":"785","article-title":"An open-label, concentration-controlled, randomised 6-month study of standard-dose tacrolimus + sirolimus + steroids compared to reduced-dose tacrolimus + sirolimus + steroids in renal allograft recipients [abstract]","volume":"18","author":"Bechstein","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD004290.pub2-BIB0120|cit120","unstructured":"Paczek L Bechstein W Wramner L Squifflet JP A phase II, open-label, concentration-controlled, randomized 6-month study of standard-dose tacrolimus + sirolimus + corticosteroids compared to reduced-dose tacrolimus + sirolimus + corticosteroids in renal allograft recipients [abstract] XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami (USA) 2002"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD004290.pub2-BIB0121|cit121","first-page":"464","article-title":"An open-label, concentration-controlled, randomised 6-month study of standard-dose tacrolimus + sirolimus +steroids compared to reduced-dose tacrolimus + sirolimus + steroids in renal allograft recipients [abstract]","volume":"3","author":"Paczek","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD004290.pub2-BIB0122|cit122","first-page":"464","article-title":"A regimen of sirolimus and reduced-dose tacrolimus results in improved renal allograft function: combined analysis of the north american target, european and australian sirolimus-tacrolimus trials [abstract]","volume":"3","author":"Whelchel","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD004290.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/00007691-200410000-00007","article-title":"Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation","volume":"26","author":"Kovarik","year":"2004","journal-title":"Therapeutic Drug Monitoring"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD004290.pub2-BIB0124|cit124","first-page":"296","article-title":"Efficacy and safety of 2 doses of everolimus combined with reduced dose neoral\u00ae in de novo kidney transplant recipients: 12 months analysis [abstract]","volume":"4","author":"Magee","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"9 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0127|cit125","first-page":"15","article-title":"Concentration-controlled everolimus (Certican): combination with reduced dose calcineurin inhibitors","volume":"79","author":"Pascual","year":"2005","journal-title":"Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD004290.pub2-BIB0125|cit126","first-page":"786","article-title":"Excellent renal function with concentration-controlled everolimus, reduced exposure to neoral, and steroids in de novo kidney transplant recipients: results of a 6 months efficacy and safety analysis [abstract]","volume":"18","author":"Pascual","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0126|cit127","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00007890-200407271-00713","article-title":"12 month clinical trial results of safety and efficacy of trough-controlled certican\u00ae dosing with reduced neoral\u00ae exposure in de novo kidney transplant recipients [abstract]","volume":"78","author":"Pascual","year":"2004","journal-title":"Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD004290.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1600-6143.2004.00389.x","article-title":"Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies","volume":"4","author":"Vitko","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD004290.pub2-BIB0129|cit129","first-page":"251","article-title":"Pharmacokinetics, safety and efficacy of mycophenolate mofetil in combination with sirolimus vs cyclosporine in renal transplant patients [abstract]","volume":"4","author":"Pescovitz","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004290.pub2-BIB0130|cit130","first-page":"916","article-title":"Assessment of renal function in de novo renal transplant patients receiving either sirolimus or everolimus in addition to ciclosporine A [abstract]","volume":"12","author":"Rostaing","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004290.pub2-BIB0131|cit131","first-page":"364","article-title":"The safety and efficacy of reduced- and standard-target concentration tacrolimus plus sirolimus in renal allograft recipients: preliminary 6-month results from Australia [abstract]","volume":"13","author":"Russ","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD004290.pub2-BIB0132|cit132","unstructured":"Russ G Campbell S Chadban S Eris J O'Connell P Pussell B Walker R for the Australian Rapa-Tac Study Group Comparison of reduced-and standard-target concentration tacrolimus plus sirolimus in renal allograft recipients: preliminary 6-month results [abstract] Transplantation Society of Australia & New Zealand; 2003 Apr 9-11; Canberra (Australia) 2003 64"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0041-1345(03)00210-0","article-title":"Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients","volume":"35","author":"Russ","year":"2003","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD004290.pub2-BIB0134|cit134","first-page":"464","article-title":"A regimen of sirolimus and reduced-dose tacrolimus results in improved renal allograft function: combined analysis of the north American target, European and Australian sirolimus-tacrolimus trials [abstract]","volume":"3","author":"Whelchel","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD004290.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/01.ASN.0000102469.32182.8C","article-title":"Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function","volume":"15","author":"Stallone","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD004290.pub2-BIB0136|cit136","first-page":"563","article-title":"Sirolimus prolongs delayed graft function in recipients of sub-optimal cadaveric kidney donors [abstract]","volume":"3","author":"Stallone","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00007890-200407271-00241","article-title":"The effects of calcineurin inhibitor avoidance on renal function and graft histology after kidney transplantation: a prospective, randomized comparison of tacrolimus and sirolimus [abstract]","volume":"78","author":"Dean","year":"2004","journal-title":"Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD004290.pub2-BIB0139|cit138","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/01.TP.0000123082.31092.53","article-title":"Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus","volume":"77","author":"Dean","year":"2004","journal-title":"Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD004290.pub2-BIB0138|cit139","first-page":"229","article-title":"Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus [abstract]","volume":"4","author":"Dean","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD004290.pub2-BIB0140|cit140","first-page":"189","article-title":"Frequency of polyomavirus-associated nephropathy in a randomized controlled trial of tacrolimus versus sirolimus-based immunosuppression [abstract]","volume":"3","author":"Hamad","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD004290.pub2-BIB0141|cit141","first-page":"217","article-title":"Metabolic complications after renal transplantation: a comparison of sirolimus vs tacrolimus-based immunosuppression [abstract]","volume":"3","author":"Kudva","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD004290.pub2-BIB0142|cit142","first-page":"475","article-title":"Avoiding calcineurin-inhibitors in renal transplantation: a randomized trial of sirolimus vs tacrolimus [abstract]","volume":"3","author":"Larson","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD004290.pub2-BIB0144|cit143","first-page":"237","article-title":"Kidney transplantation without calcineurin-inhibitors: a randomized trial of sirolimus vs tacrolimus [abstract]","volume":"2","author":"Larson","year":"2002","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD004290.pub2-BIB0143|cit144","unstructured":"Larson TS Velosa JA Prieto M Lund WJ Griffin MD Gloor JM Kidney transplantation without calcineurin-inhibitors: a randomized trial of sirolimus vs tacrolimus [abstract] XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami (USA) 2002"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD004290.pub2-BIB0145|cit145","first-page":"214","article-title":"Obesity increases wound complications in sirolimus-treated renal allograft recipients [abstract]","volume":"3","author":"Lund","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0041-1345(03)00226-4","article-title":"Kidney transplantation without calcineurin inhibitors using sirolimus","volume":"35","author":"Stegall","year":"2003","journal-title":"Transplantation Proceedings"},{"issue":"12","key":"10.1002\/14651858.CD004290.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1097\/01.TP.0000071301.86299.75","article-title":"A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients","volume":"75","author":"Hooff","year":"2003","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD004290.pub2-BIB0148|cit148","unstructured":"Boger R Certican (RAD; Everolimus), The proliferation signal inhibitor, is complementary with neoral in preventing acute allograft rejection [abstract] 2001 A Transplant Odyssey; 2001 Aug 20-23; Istanbul (Turkey) 2001 18"},{"key":"10.1002\/14651858.CD004290.pub2-BIB0149|cit149","unstructured":"Dantal J Vitko S Margreiter R Weimar W Viljoen H Boger R RAD 201 Study Group Incidence of cytomegalovirus and other viral infections is significantly less in patients receiving certican (RAD;everolimus) versus mmf while maintaining good efficacy [abstract] 10th ESOT & 12th ETCO Congress; 2001 Oct 6-11; Lisbon (Portugal) 2001"},{"key":"10.1002\/14651858.CD004290.pub2-BIB0150|cit150","unstructured":"Holmes M Economic evaluation of everolimus (Certican) versus mycophenolate mofetil as part of triple immunosuppressive therapy in de novo renal transplant recipients [abstract] International Society of Organ Transplantation Meeting; 2002; Miami (USA) 2002 2148"},{"issue":"4","key":"10.1002\/14651858.CD004290.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1432-2277.2004.tb00426.x","article-title":"Economic evaluation of everolimus versus mycophenolate mofetil in combination with cyclosporine and prednisolone in de novo renal transplant recipients","volume":"17","author":"Holmes","year":"2004","journal-title":"Transplant International"},{"issue":"1","key":"10.1002\/14651858.CD004290.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mcp.2001.112969","article-title":"Longtitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine","volume":"69","author":"Kovarik","year":"2001","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD004290.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1034\/j.1600-6143.2003.00107.x","article-title":"Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation","volume":"3","author":"Kovarik","year":"2003","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD004290.pub2-BIB0154|cit154","unstructured":"Kovarik JM Rordorf C McMahon L Berthier S Boger R Toward defining a therapeutic range for everolimus in de novo kidney transplantation based on exposure-response relationships [abstract] 10th ESOT & 12th ETCO Congress; 2001 Oct 6-11; Lisbon (Portugal) 2001"},{"issue":"2","key":"10.1002\/14651858.CD004290.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1399-0012.2005.00326.x","article-title":"Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data","volume":"19","author":"Lorber","year":"2005","journal-title":"Clinical Transplantation"},{"key":"10.1002\/14651858.CD004290.pub2-BIB0156|cit156","unstructured":"Margreiter R Vitko S Weimar W Dantal J Viljoen H Boger R the RAD 201 Study Group Certican (RAD; everolimus), the proliferation signal inhibitor, is complementary with neoral in preventing acute allograft rejection [abstract] 10th ESOT & 12th ETCO Congress; 2001 Oct 6-11; Lisbon (Portugal) 2001"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD004290.pub2-BIB0157|cit157","first-page":"499","article-title":"36-month results of an international study with everolimus for the prevention of allograft rejection in de novo kidney transplant recipients [abstract]","volume":"18","author":"Neumayer","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD004290.pub2-BIB0158|cit158","unstructured":"Noronha IL Eisen HJ Pedersen TR Rivero E Long-term predicted probability of coronary heart disease in renal transplant recipients treated with everolimus or mmf: an estimation based on the first year of treatment by applying a Framingham prediction model [abstract] 10th ESOT & 12th ETCO Congress; 2001 Oct 6-11; Lisbon (Portugal) 2001"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD004290.pub2-BIB0159|cit159","first-page":"459","article-title":"36-month results of an international study with everolimus for the prevention of allograft rejection in de novo kidney transplant recipients [abstract]","volume":"3","author":"Oppenheimer","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004290.pub2-BIB0160|cit160","first-page":"474","article-title":"International, double-blind, parallel group study of the safety and efficacy of certican (rad) versus mycophenolate mofetil (mmf) in combination with neoral and steroids [abstract]","volume":"1","author":"Vitko","year":"2001","journal-title":"American Journal of Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD004290.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1097\/01.TP.0000141094.34903.54","article-title":"Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients","volume":"78","author":"Vitko","year":"2004","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD004290.pub2-BIB0162|cit162","unstructured":"Weimar W Vitko S Margreiter R Dantal J Viljoen H Boger R the RAD 201 Study Group Hyperlipidemia associated with a certican (RAD;everolimus) containing immunosuppressive regimen is reversible and responsive to lipid lowering therapies [abstract] 10th ESOT & 12th ETCO Congress; 2001 Oct 6-11; Lisbon (Portugal) 2001"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD004290.pub2-BIB0163|cit163","first-page":"571","article-title":"Tacrolimus with MMF or two different doses of sirolimus in kidney transplantation: a large randomised multicentre study [abstract]","volume":"5","author":"Salmela","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD004290.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1600-6143.2004.00389.x","article-title":"Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies","volume":"4","author":"Vitko","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD004290.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/00007890-200407271-00299","article-title":"Tacrolimus in combination with two different sirolimus doses versus a tacrolimus\/mmf-based regimen: a large, randomised clinical study in renal transplantation [abstract]","volume":"78","author":"Vitko","year":"2004","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD004290.pub2-BIB0166|cit166","unstructured":"Non systematic results pooled from Vitko 2001 (201) and Kaplan 2001 (251) See individual studies for reference lists"},{"key":"10.1002\/14651858.CD004290.pub2-BIB0167|cit167","unstructured":"Australia New Zealand Dialysis Transplant Registry ANZDATA Registry 24th Report http:\/\/www.anzdata.org.au\/ (accessed October 2002)"},{"key":"10.1002\/14651858.CD004290.pub2-BIB0168|cit168","unstructured":"Chadban S AZDATA 2003 Registry Report. Chapter 8: Transplantation http:\/\/www.anzdata.org.au\/"},{"issue":"1","key":"10.1002\/14651858.CD004290.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1002\/14651858.CD004290.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/9780470693926.ch15","article-title":"Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis","volume-title":"Systematic reviews in healthcare","author":"Deeks","year":"2001"},{"issue":"6964","key":"10.1002\/14651858.CD004290.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","article-title":"Identifying relevant studies for systematic reviews","volume":"309","author":"Dickersin","year":"1994","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD004290.pub2-BIB0172|cit172","first-page":"1220","article-title":"Everolimus Novartis","volume":"2","author":"Dumont","year":"2001","journal-title":"Current Opinion in Investigational Drugs"},{"issue":"109","key":"10.1002\/14651858.CD004290.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004290.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/9780470693926.ch3","article-title":"Problems and limitations in conducting systematic reviews.","volume-title":"Systematic reviews in health care","author":"Egger","year":"2001"},{"issue":"11","key":"10.1002\/14651858.CD004290.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/01.TP.0000144181.47045.FE","article-title":"A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results","volume":"78","author":"Gallagher","year":"2004","journal-title":"Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD004290.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1056\/NEJM200003023420901","article-title":"Improved graft survival after renal transplantation in the United States, 1988 to 1996","volume":"342","author":"Hariharan","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD004290.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1600-6143.2004.00484.x","article-title":"Surrogate markers for long-term renal allograft survival","volume":"4","author":"Hariharan","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"7414","key":"10.1002\/14651858.CD004290.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"10","key":"10.1002\/14651858.CD004290.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1097\/00007890-200005270-00019","article-title":"Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management","volume":"69","author":"Hong","year":"2000","journal-title":"Transplantation"},{"issue":"11","key":"10.1002\/14651858.CD004290.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1517\/14656566.2.11.1903","article-title":"Sirolimus: a comprehensive review","volume":"2","author":"Kahan","year":"2001","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"12","key":"10.1002\/14651858.CD004290.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1046\/j.1600-6135.2003.00275.x","article-title":"Poor predictive value of serum creatinine for renal allograft loss","volume":"3","author":"Kaplan","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD004290.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/j.1600-6143.2005.00853.x","article-title":"Long-term deterioration of kidney allograft function","volume":"5","author":"Kasiske","year":"2005","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD004290.pub2-BIB0183|cit183","unstructured":"Lefebvre C McDonald S Development of a sensitive search strategy for reports of randomised controlled trials in EMBASE Fourth International Cochrane Colloquium; 1996 Oct 20-24; Adelaide (Australia) 1996"},{"issue":"9","key":"10.1002\/14651858.CD004290.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1111\/j.1600-6143.2005.01019.x","article-title":"Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus","volume":"5","author":"Meier-Kriesche","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD004290.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1111\/j.1600-6143.2005.00931.x","article-title":"Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials","volume":"5","author":"Mulay","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD004290.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1097\/00007890-199506270-00007","article-title":"Predicting glomerular filtration rate after kidney transplantation","volume":"59","author":"Nankivell","year":"1995","journal-title":"Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD004290.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00007691-200202000-00010","article-title":"Early clinical experience with a novel rapamycin derivative","volume":"24","author":"Nashan","year":"2002","journal-title":"Therapeutic Drug Monitoring"},{"issue":"8","key":"10.1002\/14651858.CD004290.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/01.TP.0000060740.69785.09","article-title":"Predicting long-term kidney graft survival: can new trials be performed?","volume":"75","author":"Paraskevas","year":"2003","journal-title":"Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD004290.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMra011295","article-title":"Strategies to improve long-term outcomes after renal transplantation","volume":"346","author":"Pascual","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD004290.pub2-BIB0190|cit190","first-page":"762","article-title":"The pleiotropic effects of mTor inhibitors","volume":"17","author":"Ponticelli","year":"2004","journal-title":"Journal of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD004290.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1523-1755.2001.00460.x","article-title":"Rapamycin in transplantation: a review of the evidence","volume":"59","author":"Saunders","year":"2001","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD004290.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/00007890-199707150-00007","article-title":"SDZ RAD, a new rapamycin derivative: synergism with cyclosporine","volume":"64","author":"Schuurman","year":"1997","journal-title":"Transplantation"},{"issue":"13","key":"10.1002\/14651858.CD004290.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa042831","article-title":"Sirolimus for Kaposi's sarcoma in renal-transplant recipients","volume":"352","author":"Stallone","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004290.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1365-2249.1997.d01-984.x","article-title":"Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection","volume":"108","author":"Stepkowski","year":"1997","journal-title":"Clinical & Experimental Immunology"},{"key":"10.1002\/14651858.CD004290.pub2-BIB0195|cit195","unstructured":"UK Tansplant Support Service Authority National Transplant Database http:\/\/www.uktransplant.org,uk (accessed October 2002)"},{"key":"10.1002\/14651858.CD004290.pub2-BIB0196|cit196","unstructured":"Rockville M Richmond V 2000 Annual Report of the US Scientific Registry of Transplant Recipients and the Organ Procurement and Transplantation Network: Transplant data 1989-1998 http:\/\/www.unos.org (accessed October 2002)"},{"key":"10.1002\/14651858.CD004290.pub2-BIB0197|cit197","unstructured":"Immunosuppression 2004 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1994-2003 HHS\/HRSA\/OSP\/DOT and UNOS, 2004"},{"issue":"4","key":"10.1002\/14651858.CD004290.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/00007890-200002270-00006","article-title":"SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts","volume":"69","author":"Viklicky","year":"2000","journal-title":"Transplantation"},{"issue":"21","key":"10.1002\/14651858.CD004290.pub2-BIB0199|cit199","first-page":"1","article-title":"Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study","volume":"9","author":"Woodroffe","year":"2005","journal-title":"Health Technology Assessment (Winchester, England)"},{"issue":"3","key":"10.1002\/14651858.CD004290.pub2-BIB0200|cit200","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004290","article-title":"Sirolimus and everolimus for kidney transplant recipients","author":"Webster","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD004290.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/01.tp.0000219703.39149.85","article-title":"Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials","volume":"81","author":"Webster","year":"2006","journal-title":"Transplantation"}],"updated-by":[{"DOI":"10.1002\/14651858.cd004290.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD004290.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:32:50Z","timestamp":1628544770000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD004290.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"additional","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2006,4,19]]},"references-count":201,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004290.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD004290.pub3","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,19]]}}}